Additional tariffs on Chinese imports of ingredients needed for dietary supplements in addition to active ingredients and excipients used in OTC drugs will increase manufacturers' costs even if they arrange to receive ingredients from firms in the US of other countries. The American Herbal Products Association told USTR that firms impacted by the additional tariff "will be faced with the need to either increase prices and thus risk sales losses, absorb additional costs by reducing profit margins, or discontinue products; each of these options risks economic harm to these companies and job losses to their employees."
Consumer health and cosmetic product ingredients are not among the nearly 300 categories the Trump administration dropped from its list of products imported from China that are subject to an additional 10% tariff that starts Sept. 24 and increases to 25% in January.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
“As we progress through 2025, it is clear that we are operating in an increasingly dynamic environment,” says Abbott CEO Robert Ford. Trump’s tariff decisions, the CRN advises dietary supplement and other consumer health product firms, are likely to change.
Iron supplements specialist PharmaNutra has penned distribution deals to take its products to additional markets across the Americas and the Middle East & North Africa.
France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.
France's food safety regulator ANSES is proposing a reproductive toxicity category 1B classification for CBD under the EU's CLP regulation, which would mean an effective ban on CBD in cosmetics and foods. However, French hemp industry association UIVEC hopes that new evidence coming out of a European Commission review will put the issue to bed before it gets that far.
HHS Secretary Kennedy ‘s opposition to allowing GRAS without notifications has support but also questions just as strong about whether FDA is authorized to conduct a rulemaking to eliminate the option.
